Existing AI platforms can only handle one or the other, which limits their overall effectiveness. According to Zhang, most existing AI tools can either recommend what materials to use or how much of each to include—but not both. Reker and Zhang aim to overcome these limitations with their new AI-guided platform, TuNa-AI (Tunable Nanoparticle platform). As a proof of concept, they used the platform to formulate a nanoparticle that more effectively encapsulated venetoclax, a chemotherapy drug used to treat leukemia. (2025) TuNa-AI: A Hybrid Kernel Machine To Design Tunable Nanoparticles for Drug Delivery.